First-phase insulin secretion: can its evaluation direct therapeutic approaches?

Gianfranco Di Giuseppe, Gea Ciccarelli, Laura Soldovieri, Umberto Capece, Chiara M A Cefalo, Simona Moffa, Enrico C Nista, Michela Brunetti, Francesca Cinti, Antonio Gasbarrini, Alfredo Pontecorvi, Andrea Giaccari*, Teresa Mezza

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo

Abstract

Our work is aimed at unraveling the role of the first-phase insulin secretion in the natural history of type 2 diabetes mellitus (T2DM) and its interrelationship with insulin resistance and with beta cell function and mass. Starting from pathophysiology, we investigate the impact of impaired secretion on glucose homeostasis and explore postmeal hyperglycemia as the main clinical feature, underlining its rele-vance in the management of the disease. We also review dietary and pharmaco-logical approaches aimed at improving early secretory defects and restoring residual beta cell function. Furthermore, we discuss possible approaches to detect early secretory defects in clinical practice. By providing a journey through human and animal data, we attempt a unification of the recent evidence in an effort to offer a new outlook on beta cell secretion.
Lingua originaleInglese
pagine (da-a)216-230
Numero di pagine15
RivistaTrends in Endocrinology and Metabolism
Volume34
Numero di pubblicazione4
DOI
Stato di pubblicazionePubblicato - 2023

All Science Journal Classification (ASJC) codes

  • Endocrinologia, Diabete e Metabolismo
  • Endocrinologia

Keywords

  • first phase
  • insulin secretion
  • postmeal hyperglycemia
  • type 2 diabetes
  • β cell function

Fingerprint

Entra nei temi di ricerca di 'First-phase insulin secretion: can its evaluation direct therapeutic approaches?'. Insieme formano una fingerprint unica.

Cita questo